Trial Profile
Randomized Phase II Trial of Everolimus Versus Placebo as Adjuvant Therapy in Patients with Locally Advanced Squamous Cell Cancer of the Head and Neck (SCCHN).
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Everolimus (Primary)
- Indications Head and neck cancer; Squamous cell cancer
- Focus Therapeutic Use
- 25 Mar 2020 Status changed from active, no longer recruiting to discontinued.
- 29 Feb 2020 Primary endpoint (2 year Tumor Progression free survival) has not been met.
- 29 Feb 2020 Results presented at the 2020 Multidisciplinary Head and Neck Cancers Symposium